The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Abstract
Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 2×
“potent insulinotropic peptides both in vitro (9), and in rodents, pigs, and human subjects in vivo (10–12).”
BackgroundSelf-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, P. B., Moritz, W., Müller, B., Vallejo, M., Thomas, M. K., & Habener, J. F. (2001) · Diabetes · doi:10.2337/diabetes.50.3.521 · Cited by 785
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Self-citationAlbumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2005) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,545
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Self-citationImpact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Self-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Self-citationGlucose Metabolism and Regulation: Beyond Insulin and Glucagon
Aronoff, S. L., Berkowitz, K., Shreiner, B., & Want, L. (2004) · Diabetes Spectrum · doi:10.2337/diaspect.17.3.183 · Cited by 569
cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M., & Montminy, M. (2003) · Genes & Development · doi:10.1101/gad.1097103 · Cited by 543
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Self-citationInternational Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
Self-citationIncretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
Donath, M. Y., & Halban, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1336-4 · Cited by 430
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416
“In rodents, GLP-1 has been shown to stimulate -cell growth and differentiation and inhibit -cell apoptosis (5).”
BackgroundPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Holz, G. G. (2004) · Diabetes · doi:10.2337/diabetes.53.1.5 · Cited by 391
Clinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 375
Gut microbiota, probiotics and diabetes
Gomes, A. C., Bueno, A. A., de Souza, R. G. M., & Mota, J. F. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-60 · Cited by 363
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Borg, C. M., le Roux, C. W., Ghatei, M. A., Bloom, S. R., Patel, A. G., & Aylwin, S. J. B. (2006) · British Journal of Surgery · doi:10.1002/bjs.5227 · Cited by 318
A role for chemistry in stem cell biology
Ding, S., & Schultz, P. G. (2004) · Nature Biotechnology · doi:10.1038/nbt987 · Cited by 311
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y., & Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci25483 · Cited by 290
Self-citationGlucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Given the potential of GLP-1 to inhibit B-cell apoptosis and to increase B-cell replication as well as islet neogenesis at least in tissue culture and animal experiments [74,137,140,271], GLP-1 may delay or even reverse the development of type 2 diabetes.”
BackgroundRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Drucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Self-citationPreservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Proliferation of sorted human and rat beta cells
Parnaud, G., Bosco, D., Berney, T., Pattou, F., Kerr-Conte, J., Donath, M. Y., Bruun, C., Mandrup-Poulsen, T., Billestrup, N., & Halban, P. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0855-1 · Cited by 232
Cani, P. D., Daubioul, C. A., Reusens, B., Remacle, C., Catillon, G., & Delzenne, N. M. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06100 · Cited by 197
le Roux, C. W., Borg, C., Wallis, K., Vincent, R. P., Bueter, M., Goodlad, R., Ghatei, M. A., Patel, A., Bloom, S. R., & Aylwin, S. J. B. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181d3d21f · Cited by 176
Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Self-citationGrowth factors and beta cell replication
Vasavada, R. C., Gonzalez-Pertusa, J. A., Fujinaka, Y., Fiaschi-Taesch, N., Cozar-Castellano, I., & Garcia-Ocaña, A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.003 · Cited by 133
Changes in gut hormones after bariatric surgery
Vincent, R. P., & Le Roux, C. W. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03164.x · Cited by 100
Marzioni, M., Alpini, G., Saccomanno, S., Candelaresi, C., Venter, J., Rychlicki, C., Fava, G., Francis, H., Trozzi, L., Glaser, S., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.007 · Cited by 96
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Wu, X., Li, S., Xue, P., & Li, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.018 · Cited by 92
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
Leech, C. A., Chepurny, O. G., & Holz, G. G. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00010-2 · Cited by 76
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
Marzioni, M., Alpini, G., Saccomanno, S., Candelaresi, C., Venter, J., Rychlicki, C., Fava, G., Francis, H., Trozzi, L., & Benedetti, A. (2009) · Gut · doi:10.1136/gut.2008.150870 · Cited by 73
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
Bray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
Zhao, T. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-90 · Cited by 45
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“GLP-1 has also been shown to contribute to islet cell growth and differentiation in rodents, but GLP-1 may also exert trophic effects on the b cells by inhibition of apoptosis and the latter effect may also be observed in human b cells [27].”
BackgroundGlucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
Lazard, D., Vardi, P., & Bloch, K. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2294 · Cited by 24
Metadata
- Authors
- Drucker, D. J.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-02-01
- Volume
- 17
- Issue
- 2
- Pages
- 161-171
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2107076497
- Cited by
- 483
- References
- 105
- FWCI
- 34.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.